Author:
Niu J.,Maurice-Dror C.,Lee D.H.,Kim D.-W.,Nagrial A.,Voskoboynik M.,Chung H.C.,Mileham K.,Vaishampayan U.,Rasco D.,Golan T.,Bauer T.M.,Jimeno A.,Chung V.,Chartash E.,Lala M.,Chen Q.,Healy J.A.,Ahn M.-J.
Reference19 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. NCCN clinical practice guidelines in oncology. Non-small cell lung cancer. Version 4. 2021,2021
3. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019
4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019
5. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018
Cited by
150 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献